valproic acid has been researched along with gemcitabine in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (15.00) | 29.6817 |
| 2010's | 14 (70.00) | 24.3611 |
| 2020's | 3 (15.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Hanaoka, J; Ikemoto, T; Imura, S; Iwahashi, S; Mori, H; Morine, Y; Saito, Y; Shimada, M; Sugimoto, K; Utsunomiya, T | 1 |
| Hanaoka, J; Ikemoto, T; Imura, S; Iwahashi, S; Mori, H; Morine, Y; Saito, Y; Shimada, M; Utsunomiya, T | 1 |
| Koga, H; Sata, M; Selvendiran, K; Sivakumar, R; Torimura, T; Ueno, T; Yoshida, T | 1 |
| de Boer, JP; Greijer, AE; Huitema, AD; Juwana, H; Middeldorp, JM; Novalic, Z; Tan, IB; Verkuijlen, SA; Wildeman, MA | 1 |
| Cogdill, AP; Cooper, ZA; Ferrone, CR; Fiedler, A; Frederick, DT; Garber, HR; Rosenberg, L; Thayer, SP; Wargo, JA; Warshaw, AL | 1 |
| Dantzig, AH; Donoho, GP; Durland-Busbice, S; Perkins, EJ; Pratt, SE; Shepard, RL; Starling, JJ; Wickremsinhe, ER | 1 |
| Bondarev, GN; Filatov, MV; Ibatulin, FM; Kovalëv, RA; Stam, TA | 1 |
| de Boer, JP; Greijer, AE; Huitema, AD; Juwana, H; Middeldorp, JM; Novalić, Z; Stoker, SD; Tan, IB; Verkuijlen, SA; Wildeman, MA | 1 |
| Akada, J; Baron, B; Kitagawa, T; Kuramitsu, Y; Nakamura, K; Tokuda, K; Wang, Y | 1 |
| Barreca, GS; Costa, C; Donato, G; Focà, A; Giancotti, A; La Boria, A; Liberto, MC; Pisani, V; Roveda, L; Strazzulla, A; Torti, C; Tucci, L; Zicca, E | 1 |
| Chang, KP; Chang, YS; Fan, HC; Hsieh, CH; Hsu, CL; Huang, Y; Huang, YC; Kuo, YC; Lee, LY; Li, HP; Lin, AC; Lin, TL; Lui, KW; Wang, HM | 1 |
| de Greeuw, I; Eersels, JLH; Greijer, AE; Middeldorp, JM; Molthoff, CFM; Novalić, Z; Verkuijlen, SAWM; Verlaan, M | 1 |
| Ji, M; Lee, EJ; Park, SM; Wang, JH | 1 |
| Digiovanni, MG; Lacomb, JF; Luo, D; Mackenzie, GG; Rigas, B; Wei, R; Williams, JL | 1 |
| Garri, DD; Karamysheva, АF; Moiseeva, NI; Saakyan, SV; Tsygankov, АY | 1 |
2 review(s) available for valproic acid and gemcitabine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Nasopharyngeal carcinoma: review of the literature with a focus on therapeutical implications.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Evidence-Based Medicine; Gemcitabine; Humans; Immunotherapy, Adoptive; Lymphocyte Activation; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Treatment Outcome; Valproic Acid | 2015 |
1 trial(s) available for valproic acid and gemcitabine
| Article | Year |
|---|---|
Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma.
Topics: Adult; Antibodies, Viral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; DNA, Viral; Female; Gemcitabine; Herpesvirus 4, Human; Humans; Immunoglobulin A; Immunoglobulin G; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; T-Lymphocytes; Valproic Acid; Virus Latency | 2015 |
17 other study(ies) available for valproic acid and gemcitabine
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-α on pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Drug Interactions; Gemcitabine; Gene Expression Regulation, Neoplastic; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Interferon alpha-2; Interferon-alpha; Pancreatic Neoplasms; Polyethylene Glycols; Recombinant Proteins; Repressor Proteins; Trans-Activators; Valproic Acid | 2011 |
Histone deacetylase inhibitor enhances the anti-tumor effect of gemcitabine: a special reference to gene-expression microarray analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; Drug Synergism; Epigenomics; Gemcitabine; Gene Expression Profiling; Gene Regulatory Networks; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Humans; Microarray Analysis; Valproic Acid | 2011 |
PPARγ potentiates anticancer effects of gemcitabine on human pancreatic cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Deoxycytidine; fas Receptor; Gemcitabine; Histone Deacetylases; Humans; Ligands; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Pioglitazone; PPAR gamma; Receptors, Death Domain; Receptors, TNF-Related Apoptosis-Inducing Ligand; Rosiglitazone; Thiazolidinediones; Valproic Acid; Xenograft Model Antitumor Assays | 2012 |
Cytolytic virus activation therapy for Epstein-Barr virus-driven tumors.
Topics: Antibodies, Viral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Line, Tumor; Deoxycytidine; DNA, Viral; Dose-Response Relationship, Drug; Female; Gemcitabine; Herpesvirus 4, Human; Humans; Immunoglobulin G; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Staging; Treatment Outcome; Valproic Acid; Viral Load; Virus Activation | 2012 |
Targeting the MAGE A3 antigen in pancreatic cancer.
Topics: Adenocarcinoma; Antigens, Neoplasm; Azacitidine; Cell Line, Tumor; Chromatin Assembly and Disassembly; Cytokines; Decitabine; Deoxycytidine; DNA Methylation; Gemcitabine; Humans; Hydroxamic Acids; Immunotherapy; Male; Neoplasm Proteins; Pancreas; Pancreatic Neoplasms; Receptors, Antigen, T-Cell; T-Lymphocytes; Testis; Valproic Acid | 2012 |
Efficacy of low-dose oral metronomic dosing of the prodrug of gemcitabine, LY2334737, in human tumor xenografts.
Topics: Administration, Metronomic; Administration, Oral; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Deoxyuridine; Disease Models, Animal; Dose-Response Relationship, Drug; Gemcitabine; Gene Expression; HCT116 Cells; Humans; Lung Neoplasms; Mice; Prodrugs; Valproic Acid; Xenograft Model Antitumor Assays | 2013 |
[Possibilities of epigenetic anti-tumor therapy in in-vitro models].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Butyric Acid; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Epigenesis, Genetic; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Neoplasms; Radiotherapy, Adjuvant; Salts; Sodium; Time Factors; Valproic Acid | 2012 |
The Histone Deacetylase Inhibitor Valproic Acid Sensitizes Gemcitabine-Induced Cytotoxicity in Gemcitabine-Resistant Pancreatic Cancer Cells Possibly Through Inhibition of the DNA Repair Protein Gamma-H2AX.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA Repair; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Histone Deacetylase Inhibitors; Histones; Humans; Pancreatic Neoplasms; Valproic Acid | 2015 |
Application of a patient-derived xenograft model in cytolytic viral activation therapy for nasopharyngeal carcinoma.
Topics: Animals; Anticonvulsants; Antimetabolites, Antineoplastic; Antiviral Agents; Apoptosis; Carcinoma; Cell Proliferation; Deoxycytidine; DNA, Viral; Drug Therapy, Combination; Epstein-Barr Virus Infections; Ganciclovir; Gemcitabine; Gene Expression Profiling; Herpesvirus 4, Human; Humans; Immunoenzyme Techniques; Male; Mice; Mice, Inbred NOD; Mice, SCID; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Oncolytic Virotherapy; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Valproic Acid; Viral Load; Virus Activation; Xenograft Model Antitumor Assays | 2015 |
Cytolytic virus activation therapy and treatment monitoring for Epstein-Barr virus associated nasopharyngeal carcinoma in a mouse tumor model.
Topics: Animals; Antiviral Agents; Carcinoma; Deoxycytidine; Disease Models, Animal; DNA, Viral; Epstein-Barr Virus Infections; Ganciclovir; Gemcitabine; Herpesvirus 4, Human; Humans; Mice; Mice, Nude; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Treatment Outcome; Tumor Cells, Cultured; Valproic Acid; Viral Load; Virus Activation | 2017 |
HDAC inhibitors, trichostatin A and valproic acid, increase E‑cadherin and vimentin expression but inhibit migration and invasion of cholangiocarcinoma cells.
Topics: Cadherins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cholangiocarcinoma; Deoxycytidine; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Neoplasm Invasiveness; Valproic Acid; Vimentin | 2018 |
Phospho-valproic acid (MDC-1112) reduces pancreatic cancer growth in patient-derived tumor xenografts and KPC mice: enhanced efficacy when combined with gemcitabine.
Topics: Abnormalities, Multiple; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Gemcitabine; Humans; Keratoconus; Mice; Organophosphates; Pancreatic Neoplasms; Signal Transduction; Valproic Acid; Xenograft Model Antitumor Assays | 2020 |
Assessment of the Chemosensitivity of Uveal Melanoma Cells Ex Vivo.
Topics: Adult; Aged; Antineoplastic Agents; Benzeneacetamides; Busulfan; Cell Proliferation; Cell Survival; Choroid Neoplasms; Deoxycytidine; Diterpenes; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Male; Melanoma; Middle Aged; Phenylacetates; Primary Cell Culture; Retinyl Esters; Tumor Cells, Cultured; Uveal Neoplasms; Valproic Acid | 2020 |